Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Kylonova (Xiamen) Biopharma co., LTD.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 18 to 80 years
Clinical diagnosis of atherosclerotic cardiovascular disease with elevated Lp(a)
You may not be if
Have moderate to severe heart failure (New York Heart Association \[NYHA\] Functional Classification III or IV during Screening) or last known left ventricular ejection fraction \<30%
Have uncontrolled hypertension (systolic blood pressure \[SBP\] ≥160 mmHg or diastolic blood pressure \[DBP\] ≥100 mmHg)
Have uncontrolled cardiac arrhythmia defined as recurrent and highly symptomatic ventricular tachycardia, atrial fibrillation with rapid ventricular response, or supraventricular tachycardia that are not controlled by medications, in the past 3 months prior to randomization
Have had any malignancy within 5 years prior to randomization (except for non-melanoma skin cancers, cervical in-situ carcinoma, breast ductal carcinoma in situ, or stage 1 prostate carcinoma that has been successfully treated)
Clareo Health | Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)
